In one of their first ever ac­qui­si­tions, Re­lay bets $85M cash on a new AI-based screen­ing ap­proach

Al­though they’ve nev­er been short for cash, Re­lay Ther­a­peu­tics hasn’t been one for ac­qui­si­tions in its 5-year his­to­ry, fo­cus­ing in­stead on de­vel­op­ing its own tools …

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER